logo-loader

Clinigen to manage chemotherapy overdose treatment programme for BTG

Published: 03:20 31 Jul 2013 EDT

no_picture_pai

Clinigen’s (LON:CLIN) Global Access Programs (GAP) arm has extended its distribution agreement with BTG (LON:BTG) subsidiary Protherics Medicines to a third product.

GAP will exclusively manage a named patient programme in 37 European countries for uridine triacetate, used as an antidote to overexposure to the widely used chemotherapy drug 5-fluorouracil (5-FU).

Over 10,000 patients every year across Europe are estimated to be overdosed with 5-FU and although not yet approved in Europe the programme will allow uridine triacetate to be administered to named patients.

Drug developer Wellstat Therapeutics granted named patient supply rights to BTG in Europe in 2012. Clinigen will provide the named patients access to uridine triacetate 24 hours a day, 7 days a week.

Mark Corbett, Clinigen GAP’s senior vice president, said: "We are pleased to be extending our current agreement with BTG to add a third programme to the portfolio already handled by Clinigen.

“5-FU overexposure is an important unmet medical need and making available the supply of uridine triacetate on a named patient basis will provide healthcare professionals access to this investigational antidote to treat patients."

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

58 minutes ago